bluebird bio (BLUE)
(Delayed Data from NSDQ)
$1.11 USD
+0.03 (2.78%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.11 USD
+0.03 (2.78%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 7.61% and 147.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for bluebird bio (BLUE) This Earnings Season?
by Zacks Equity Research
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Ensign Group's (ENSG) Earnings in Q1?
by Zacks Equity Research
Ensign Group's (ENSG) Q1 results are likely to reflect a better revenue stream.
bluebird bio (BLUE) Catches Eye: Stock Jumps 6%
by Zacks Equity Research
bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA
by Zacks Equity Research
Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.
Bluebird (BLUE) Down 47.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bluebird (BLUE) Down 47.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
bluebird (BLUE) reports a wider-than-expected loss and in-line revenues for the fourth quarter of 2019.
Bluebird Bio (BLUE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bluebird Bio (BLUE) closed at $91.77, marking a +1.75% move from the previous day.
Novo Nordisk's Shares Up in a Year on Pipeline Progress
by Zacks Equity Research
Novo Nordisk's (NVO) shares have gained in the past year as it makes significant progress in pipeline development.
bluebird (BLUE) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
bluebird (BLUE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar
by Zacks Equity Research
The biotech sector witnesses pipeline updates from the annual ASH meet.
Fate (FATE) Announces Encouraging Data on Immunotherapies
by Zacks Equity Research
Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.
bluebird Reports Positive Top-Line Data on Myeloma Drug
by Zacks Equity Research
bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.
Are Options Traders Betting on a Big Move in bluebird (BLUE) Stock?
by Zacks Equity Research
Investors need to pay close attention to bluebird (BLUE) stock based on the movements in the options market lately.
Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD
by Zacks Equity Research
Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.
Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease
by Zacks Equity Research
Novartis (NVS) gets FDA nod for Adakveo to reduce the frequency of pain crises in adult and pediatric SCD patients.
Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -5.67% and -15.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment
by Zacks Equity Research
Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.
bluebird Inks Genome Editing Research Deal With Novo Nordisk
by Zacks Equity Research
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
FDA Grants Priority Review to Global Blood's SCD Candidate
by Zacks Equity Research
The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.
Bluebird (BLUE) Down 19.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) posts wider-than-expected loss, while sales beat estimates in the second quarter of 2019.
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -17.16% and 25.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?